NASDAQ: SKINBeauty Health Co Stock
$8.40-1.27 (-13.13%)
Updated May 26, 2023
SKIN Price
$8.40
Fair Value Price
$13.69
Market Cap
$1.11B
52 Week Low
$8.20
52 Week High
$16.02
P/E
-93.33x
P/B
7.55x
P/S
4.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$376.74M
Earnings
-$10.41M
Gross Margin
67%
Operating Margin
-0.7%
Profit Margin
-2.8%
Debt to Equity
5.74
Operating Cash Flow
-$81M
Beta
1.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SKIN Overview
The Beauty Health Company manufactures and sells aesthetic technologies and products worldwide. The company's flagship brand, HydraFacial, created the category of hydra dermabrasion by using a patented system to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. It also offers HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time. The Beauty Health was founded in 1997 and is headquartered in Long Beach, CA.
Zen Score
–
Industry Average (34)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SKIN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SKIN ($8.40) is undervalued by 38.64% relative to our estimate of its Fair Value price of $13.69 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SKIN ($8.40) is significantly undervalued by 38.64% relative to our estimate of its Fair Value price of $13.69 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SKIN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SKIN due diligence checks available for Premium users.
Be the first to know about important SKIN news, forecast changes, insider trades & much more!
SKIN News
Valuation
SKIN fair value
Fair Value of SKIN stock based on Discounted Cash Flow (DCF)
Price
$8.40
Fair Value
$13.69
Undervalued by
38.64%
SKIN ($8.40) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SKIN ($8.40) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SKIN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SKIN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-93.33x
Industry
36.95x
Market
54.23x
SKIN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.55x
Industry
6.25x
SKIN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SKIN's financial health
Profit margin
Revenue
$86.3M
Net Income
-$22.3M
Profit Margin
-25.8%
SKIN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SKIN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$995.0M
Liabilities
$847.3M
Debt to equity
5.74
SKIN's short-term assets ($748.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SKIN's long-term liabilities ($774.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SKIN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.0M
Investing
-$21.7M
Financing
-$2.2M
SKIN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SKIN vs Household & Personal Product Stocks
Beauty Health Co Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.